Trials / Recruiting
RecruitingNCT07419828
A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease
A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase III Study Evaluating the Efficacy and Safety of HRS-1780 in Adult Participants With Chronic Kidney Disease
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,978 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study is a Phase III clinical trial to evaluate the superiority of HRS-1780 tablets compared with placebo in delaying renal function decline in participants with chronic kidney disease (CKD) on the basis of standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-1780 tablets | Oral tablets |
| DRUG | Placebo | Oral tablets |
Timeline
- Start date
- 2026-03-13
- Primary completion
- 2030-04-01
- Completion
- 2030-05-01
- First posted
- 2026-02-19
- Last updated
- 2026-03-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07419828. Inclusion in this directory is not an endorsement.